Proto-oncogene Pokemon in thyroid cancer: a potential promoter of tumorigenesis in papillary thyroid carcinoma

Article information

J Pathol Transl Med. 2021;55(5):317-323

Publication date (electronic) : 2021 August 09

doi : https://doi.org/10.4132/jptm.2021.06.28

Kyungseek Chang, Sung-Im Do, Kyungeun Kim, Seoung Wan Chae, In-gu Do, Hyun Joo Lee, Dong Hoon Kim, Jin Hee Sohn

Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea

Corresponding Author: Sung-Im Do, MD, PhD, Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul 03181, Korea, Tel: +82-2-2001-2389, Fax: +82-2-2001-2398, E-mail: sungim.do@samsung.com

Received 2021 April 06; Revised 2021 June 17; Accepted 2021 June 28.

Abstract

MATERIALS AND METHODS

Tissue specimens

We selected 90 cases of PTC and 25 cases of benign thyroid diseases such as nodular hyperplasia, follicular adenoma, Hashimoto’s thyroiditis, and Graves’ disease from archival cases in Kangbuk Samsung Hospital (Seoul, Republic of Korea). Controls included 68 normal thyroid tissues identified from selected cases. Tissues resected by surgeons were examined by pathologists before fixation in 10% neutral-buffered formalin for 12–24 hours, followed by thorough macroscopic evaluation and sectioning. After automatic tissue processing, sections were embedded in paraffin blocks. Four-micrometer-thick sections were cut from each formalin-fixed, paraffin-embedded (FFPE) tissue block using a rotary microtome, stained with hematoxylin and eosin, covered with a glass coverslip, followed by analysis and diagnosis by two board-certified pathologists. Clinical and pathological information were obtained from pathology reports and electrical medical information systems. Information collected included age, sex, multifocality, the greatest dimension of the tumor, presence of lymphovascular invasion, extrathyroidal extension, lymph node metastasis, number of metastatic lymph nodes, BRAF mutational status, and presence of background thyroiditis. One out of these 90 PTC patients was excluded from statistical analysis due to insufficient data (Table 1).

Table 1

Clinicopathological parameters of subjects in the PTC group

Immunohistochemistry

Immunohistochemical staining was performed using the Bond Polymer Refine Detection kit (Leica Biosystems, Newcastle upon Tyne, UK) in the Bond-Max automatic immunostainer (Leica Biosystems). ZBTB7A/Pokemon antibody (1:200, clone, Novus Biologicals, Littleton, CO, USA) was used as the primary antibody. Immunohistochemical slides were independently evaluated by two pathologists (SID and SWC). Discrepant cases were reviewed. Pokemon expression was interpreted as positive if the cell showed positivity in either the nucleus or the cytoplasm. The intensity of expression was defined as negative, weakly positive, or strongly positive (Fig. 1). Immunohistochemical expression (× 200) of Pokemon in thyroid tissues from normal (Fig. 1A–C), benign thyroid disease (Fig. 1D–F), and PTC (Fig. 1G–I) groups. Pokemon expression intensity is interpreted as negative (Fig. 1A, D, G), weakly positive (Fig. 1B, E, H), or strongly positive (Fig. 1C, F, I). It was determined using TMA cores of those with PTCs (n = 89) or benign thyroid diseases (n = 25). Pokemon expression intensity of normal thyroid tissue was determined in adjacent normal follicular cells where present, if the TMA core carried an identifiable portion of normal thyroid tissue (n = 68).

Fig. 1

Immunohistochemical expression of Pokemon in thyroid tissues of normal (A–C), benign thyroid disease (D–F), and PTC (G–I) groups. Pokemon expression intensity is interpreted as negative (A, D, G), weakly positive (B, E, H), or strongly positive (C, F, I).

RESULTS

With collected information shown in Table 1, Pokemon expression intensities in thyroid tissues of normal, benign thyroid disease, and PTC groups were determined (Table 2). Statistically significant (p < .001) differences in Pokemon expression positivity were observed between normal thyroid tissues (22.0%) and thyroid tissues from patients with benign thyroid disease (44.0%) or PTC (92.1%). Results of Pearson’s chi-square test for Pokemon expression intensity in normal, benign, and PTC groups are shown in Supplementary Tables S1–S3. The difference in Pokemon expression intensity between normal and benign thyroid disease groups was statistically significant (p = .035). The difference in Pokemon expression intensity between normal and PTC groups was also statistically significant (p < .001). Similarly, the difference in Pokemon expression intensity between benign thyroid disease and PTC was significant (p < .001).

Table 2

Pokemon expression intensities in thyroid tissues of normal, benign thyroid disease, and PTC groups

Pokemon expression intensity in PTC showed significant correlations with tumor size and corresponding pathologic T category groups (Table 3). Reduced mean tumor size was significantly associated with stronger Pokemon expression intensity (p = .002). Tumor size and TNM stage were also significantly associated with Pokemon expression intensity. When the tumor size was divided into three groups by a separation point at 0.5 cm and 1 cm, a tumor size less than 0.5 cm was associated with Pokemon expression intensity stronger than 66%. However, increased tumor size was associated with less strong or no Pokemon expression intensity (p = .028). Tumor size categorized by conventional TNM staging, excluding T3b and T4 groups for gross extrathyroidal extension to and beyond strap muscles, showed evident negative concordance with Pokemon expression intensity (p = .010). T1a group was associated with expression greater than 66%, whereas groups T1b, T2, and T3a were collectively associated with no or weak expression (p = .006). Other clinicopathological parameters did not show any significant association with Pokemon expression intensity.

Table 3

Correlations of Pokemon expression intensity with clinicopathological parameters in PTC

DISCUSSION

Pokemon can act as a genuine proto-oncogene in vivo [6]. It can repress the expression of tumor suppressor protein ARF [6]. ARF is a negative regulator of the E3 ubiquitin-protein ligase MDM2 which participates in the degradation of p53 via ubiquitin-dependent degradation by the proteasome. Reduced ARF levels can stimulate cell proliferation by decreasing the stability and activity of p53 via MDM2 [6]. Pokemon expression in malignancy is generally related to poor cancer outcome in various organs. It promotes tumorigenesis, acting as a pro-oncogene by repressing or enhancing the expression of genes involved in apoptosis, cell proliferation, and differentiation [18]. For example, Pokemon expression can promote breast cancer progression by up-regulating survivin expression [11]. In the nasopharynx, high Pokemon protein expression is closely associated with non-keratinizing nasopharyngeal carcinoma [19]. In the liver, suppression of Pokemon can impair the invasion of hepatocellular carcinoma (HCC) cells [20]. However, to the best of our knowledge, contribution of Pokemon to thyroid malignancy has yet to be reported.

Pokemon expression intensity showed a statistically significant (p = .035) difference between normal and benign thyroid disease groups in the present study. Although Pokemon expression was positive in 44% of patients with benign thyroid disease regardless of its expression intensity, it was more significantly (p < .001) associated with PTC than with benign thyroid disease (Table 2). Pokemon overexpression has also been observed in several malignancies, such as T and B cell lymphomas in transgenic mice model via direct binding of Pokemon and the tumor suppressor gene ARF [6], prostate carcinoma via increased Pokemon expression stimulated by epidermal growth factor [16], ovarian carcinomas of all four major histological types (serous, endometrioid, clear cell, and mucinous) via elevated RNA transcription [21], breast carcinoma by up-regulating survivin, a member of the inhibitor of apoptosis proteins [11]. However, the mechanism which Pokemon overexpression leads to tumorigenesis of PTC remains to be investigated.

When Pokemon expression intensity was compared according to mean PTC tumor size, stronger expression levels were observed in smaller tumors (0.9 ± 0.4 cm), whereas larger tumors (2.1 ± 1.7 cm) showed absent or weak expression. These inverse correlations were evident according to the T category of the tumor when T1a group was compared with the combined group of T1b, T2, and T3a (p = .006) (Table 3). These results were contrary to results of several previous studies of tumors involving various organs, where Pokemon expression was positively correlated with tumor size or T category of breast carcinomas [11], HCC [22], or non-small cell lung cancer [23]. These combined results of particularly strong Pokemon expression in small-sized tumors suggest that Pokemon might play an important role in malignant transformation of thyroid cells and in the early stage of PTC tumor formation, while it might have a diminished role as the tumor grows in size.

Such inverse correlation between Pokemon expression and tumor size has also been observed in oropharyngeal squamous cell carcinoma (OSCC) which shows a higher relative expression in smaller tumors (< 2 cm) and lower to no expression in larger tumors (≥ 4 cm) [18]. Although the distribution of Pokemon expression is lower in OSCC than in normal oral mucosa, Sartini et al. [18] have suggested that the downregulation of Pokemon might be related to tumor progression. Presumably, our results suggest such downregulation.

Aerobic glycolysis (the Warburg effect) is a hallmark of human cancer. It plays a crucial role in tumor growth [24]. Receptor tyrosine kinase/PI3K/AKT signaling and MYC act as pro-growth signaling factors that can upregulate aerobic glycolysis. However, Liu et al. [25] have reported that Pokemon, a proto-oncogene, unexpectedly can act as a tumor suppressor by directly binding to the promoter and repressing the transcription of genes responsible for glycolysis metabolism, such as GLUT3, PFKP, and PKM. As a result, a significant decrease in Pokemon copy number variation was observed in several types of human carcinoma in the late stage (N1, N2, N3, M1, stage IV) than in early stage (N0, M0, stage I), including esophageal carcinoma, bladder urothelial carcinoma, colorectal adenocarcinoma, lung squamous cell carcinoma, cutaneous melanoma, and low-grade glioma [25]. We believe that the mechanism underlying the inverse correlation between Pokemon expression and tumor size of PTC might be related to the unexpected negative regulation of aerobic glycolysis by Pokemon.

Regardless of its contrasting behavior in PTC, Pokemon itself is associated with malignant transformation of tumors in various organs. High levels of Pokemon expression in patients with early stages of PTC may potentially be used for screening and identifying malignancies involving other organs.

Our study was performed at a single institution with PTC cases retrieved from a two-year period, which invariably resulted in limitations involving the follow-up period of patients with PTC and their survival rates. A multi-institutional study with ethnic and racial diversity is needed to further investigate the effect of Pokemon on PTC. Larger patient groups might be needed to elucidate the effect of Pokemon on parameters showing statistical insignificance in the present study. A long-term survival study may provide further insight into the effect of Pokemon on long-term outcomes of PTC, one of the most common malignancies worldwide.

In summary, Pokemon overexpression (when compared to normal thyroid tissues) is associated with formation of PTC and benign thyroid diseases. A smaller PTC tumor shows stronger Pokemon overexpression, which supports the hypothesis that Pokemon overexpression can lead to tumorigenesis of PTC. However, a larger PTC tumor may be associated with Pokemon downregulation, which may be related to tumor progression. Targeting Pokemon in early stages could be effective in suppressing PTC formation and potentially facilitate treatment.

Supplementary Information

Article information Continued